Concepedia

Nicolas Daguindau

ND

Statistics

Publications

15

Citations

697

H-Index

13

Active since

2008

Affiliations

Centre Hospitalier Annecy Genevois(Current)

Inserm

Hôpital Saint-Louis

Hospices Civils de Lyon

Assistance Publique – Hôpitaux de Paris

Nicolas Daguindau is an author at Centre Hospitalier Annecy Genevois specializing in oncology, medicine, and lymphoma treatment response.

Publications per year

2008–2025

15

Publications

15

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Franck Morschhauser, Nathan Fowler, Pierre Feugier et al. · New England Journal of Medicine · 2018 · 362 citations · Full text

, , +15

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Franck Morschhauser, Loretta J. Nastoupil, Pierre Feugier et al. · Journal of Clinical Oncology · 2022 · 68 citations · Full text

, , +14

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma

Rémy Gressin, Nicolas Daguindau, Adrian Tempescul et al. · Haematologica · 2018 · 47 citations · Full text

, , +16

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study

Jehan Dupuis, Emmanuel Bachy, Franck Morschhauser et al. · The Lancet Haematology · 2024 · 30 citations · Full text

, , +9

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

Jehan Dupuis, Kunihiro Tsukasaki, Emmanuel Bachy et al. · Blood · 2022 · 23 citations

, , +11

1–5 of 15